Title
Subscription to a Drug Pricing Intelligence Database
Reference number
cb-219-49543150
Solicitation number
SN26003
Publication date
2026-10-22
Tender closing date
2026-11-06T12:00:00
Expected contract start date
2027-04-01
Expected contract end date
2032-03-31
Unspsc description
*Online database information retrieval service
Notice type
Advance Contract Award Notice
Procurement method
Advance contract award notice
Selection criteria
Not applicable
Trade agreements
*Canadian Free Trade Agreement (CFTA)
*Canada-UK Trade Continuity Agreement (Canada-UK TCA)
*Canada-Peru Free Trade Agreement (CPFTA)
*Canada-Ukraine Free Trade Agreement (CUFTA)
*Canada-Chile Free Trade Agreement (CCFTA)
*Canada-European Union Comprehensive Economic and Trade Agreement (CETA)
*World Trade Organization Agreement on Government Procurement (WTO GPA)
*Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP)
*Canada-Honduras Free Trade Agreement
*Canada-Colombia Free Trade Agreement
*Canada-Panama Free Trade Agreement
*Canada-Korea Free Trade Agreement (CKFTA)
Regions of opportunity
*Canada
Regions of delivery
*National Capital Region (NCR)
Contracting entity name
Patented Medicine Prices Review Board (PMPRB)
Contracting entity address line
333 Laurier Ave West
Contracting entity address city
Ottawa
Contracting entity address province
Ontario
Contracting entity address postal code
K1P 1C1
Contracting entity address country
Canada
Contact info name
S••••• B•••••••
Contact info email
s••••••••@••••••••.••.ca
Contact info address line
••• ••••••• ••• ••••
Contact info province
•••••••
Contact info postalcode
••• •••
Contact info country
••••••
Attachment
https://canadabuys.canada.ca/sites/default/files/webform/tender_notice/110717/acan-en-sn26003_0.pdf
Tender description
The PMPRB gathers intelligence and data on international pricing and reimbursement regimes/policies and trends to carry out its price review process, develop strategic advice and report on national and international trends. To perform these functions, the PMPRB needs to invest considerable resources both internally and externally to gathering and analyzing the best available information on global pricing and reimbursement of pharmaceuticals.